CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

CD19-BCMA CART Cell Therapy for Refractory SLE-LN, SSc, and pSS-PAH — Stella

Recruiting

Back to Refractory Lupus Nephritis trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

北京高博医院, Beijing, China,Beijing

Key details

Phase

Early testing / Safety & dosing

Sponsor

Beijing GoBroad Hospital

Enrollment target

~45 participants

Started

April 2025

Primary completion

July 2026

Age range

10 Years – 65 Years

Last updated March 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.

View full record on ClinicalTrials.gov